Table 1.

Participant Demographics and Clinical Characteristics by Baseline HbA1C in a Cohort of US Breast Cancer Survivors

Characteristic	HbA1C						P
	< 6.5% (n = 2,818)		6.5% to 6.9% (n = 94)		≥ 7.0% (n = 91)
	No. of Participants	%	No. of Participants	%	No. of Participants	%
Demographics
Age, years							< .001
Mean	50.6		54.1*		53.7*
SE	8.79		8.64		8.23
Ethnicity/race							< .001
White, non-Hispanic	2,436	86.4	72	76.6	61	67.0
Nonwhite	382	13.6	22	23.4	30	33.0
College educated	1,545	54.8	44	46.8	40	44.4	.017
Married	1,989	71.1	57	62.0	59	65.6	.095
Breast cancer characteristics
Cancer stage at diagnosis							< .001
I	1,109	39.4	33	35.1	25	27.8
II	1,579	56.0	51	54.3	55	61.1
IIIA	130	4.6	10	10.6	10	11.1
Grade							.978
1	1,127	40.0	39	41.5	39	43.3
2	1,018	36.1	31	33.0	29	32.2
3	231	8.2	9	9.6	7	7.8
Tumor receptor status							.336
ER positive/PR positive	1,733	62.9	62	66.7	56	62.9
ER positive/PR negative	338	12.3	8	8.6	10	11.2
ER negative/PR positive	119	4.3	1	1.1	7	7.9
ER negative/PR negative	565	20.5	22	23.7	16	18.0
Treatment
Radiation	1,729	61.4	51	54.3	68	75.6	.008
Chemotherapy	1,963	69.7	65	69.2	63	70.0	.991
Lumpectomy	1,354	48.0	36	38.3	51	56.7	.044
Mastectomy	1,463	51.9	58	61.7	39	43.3	.044
Ever-use of antiestrogen	1,909	63.7	71	75.5	67	74.4	.128
Years since diagnosis							.901
Mean	2.0		2.0		2.0
SE	1.04		1.04		0.97
Other health measures
Body mass index, kg/m2							< .001
Mean	26.9		32.1*		34.2*†
SE	5.70		7.51		8.58
Obese (≥ 30 kg/m2)	681	24.2	52	55.3	63	70.0	< .001
Poor physical health	1,169	41.5	51	54.3	56	62.2	< .001
Sedentary (< 150 MET-min/wk)	545	19.3	30	31.9	26	28.6	.001
Menopausal status							.026
Premenopausal	328	11.7	3	3.2	5	5.6
Postmenopausal	2,230	79.3	85	90.4	77	85.6
Perimenopausal	256	9.1	6	6.4	8	8.9

Abbreviations: HbA1C, hemoglobin A1C; ER, estrogen receptor; PR, progesterone receptor; MET, metabolic equivalent.

^*P < .05 for comparison with HbA1C < 6.5% category.

^†P < .05 for comparison with HbA1C 6.5% to 6.9% category.